{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:35:32Z","timestamp":1791995732377,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]},{"name":"Key Discipline Project of Fujian Medical University Union Hospital","award":["Department of Pathology"],"award-info":[{"award-number":["Department of Pathology"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-024-01573-3","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T08:23:32Z","timestamp":1731659012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Detection of genetic mutations in 855 cases of papillary thyroid carcinoma by next generation sequencing and its clinicopathological features"],"prefix":"10.1186","volume":"19","author":[{"given":"Dongliang","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"1573_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer. Rev Jama. 2024;331:425\u201335. https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"Rev Jama"},{"key":"1573_CR2","doi-asserted-by":"publisher","unstructured":"Grimm D. Recent advances in thyroid cancer research. Int J Mol Sci. 2022;23.4631. https:\/\/doi.org\/10.3390\/ijms23094631","DOI":"10.3390\/ijms23094631"},{"key":"1573_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-2505-7_1","volume":"2534","author":"AK Lam","year":"2022","unstructured":"Lam AK. Papillary thyroid carcinoma: current position in epidemiology, genomics, and classification. Methods Mol Biol. 2022;2534:1\u201315. https:\/\/doi.org\/10.1007\/978-1-0716-2505-7_1","journal-title":"Methods Mol Biol"},{"key":"1573_CR4","doi-asserted-by":"publisher","first-page":"e220293","DOI":"10.1530\/ERC-22-0293","volume":"30","author":"C Christofer Juhlin","year":"2022","unstructured":"Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2022;30:e220293. https:\/\/doi.org\/10.1530\/ERC-22-0293","journal-title":"Endocr Relat Cancer"},{"key":"1573_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Sim\u00f5es M, Tallini G, Mete O. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022;33:27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr Pathol"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fendo.2020.00102","volume":"11","author":"A Prete","year":"2020","unstructured":"Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol. 2020;11:102. https:\/\/doi.org\/10.3389\/fendo.2020.00102","journal-title":"Front Endocrinol"},{"key":"1573_CR7","doi-asserted-by":"publisher","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184\u201399. https:\/\/doi.org\/10.1038\/nrc3431","DOI":"10.1038\/nrc3431"},{"key":"1573_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","volume":"82","author":"T Hu","year":"2021","unstructured":"Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82:801\u201311. https:\/\/doi.org\/10.1016\/j.humimm.2021.02.012","journal-title":"Hum Immunol"},{"key":"1573_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12253-016-0124-z","volume":"23","author":"L Sabour","year":"2017","unstructured":"Sabour L, Sabour M, Ghorbian S. Clinical applications of next-generation sequencing in cancer diagnosis. Pathol Oncol Res. 2017;23:225\u201334. https:\/\/doi.org\/10.1007\/s12253-016-0124-z","journal-title":"Pathol Oncol Res"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"ML Marilyn","year":"2017","unstructured":"Marilyn ML, Michael D, Eric JD, Shashikant K, Neal IL, Somak R, Apostolia MT, Cindy LV, Daynna JW, Anas Y, Marina NN. Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002","journal-title":"J Mol Diagn"},{"key":"1573_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.humimm.2021","volume":"82","author":"Y Yin","year":"2021","unstructured":"Yin Y, Butler C, Zhang Q. Challenges in the application of NGS in the clinical laboratory [J]. Hum Immunol. 2021;82:812\u20139. https:\/\/doi.org\/10.1016\/j.humimm.2021.03.011","journal-title":"Hum Immunol"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"153760","DOI":"10.1016\/j.prp.2022.153760","volume":"230","author":"BM Hussen","year":"2022","unstructured":"Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract. 2022;230:153760. https:\/\/doi.org\/10.1016\/j.prp.2022.153760","journal-title":"Pathol Res Pract"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1128\/mcb.8.6.2651-2654.1988","volume":"8","author":"S Ikawa","year":"1988","unstructured":"Ikawa S, Fukui M, Ueyama Y, Tamaoki N, Yamamoto T, Toyoshima K. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol. 1988;8:2651\u20134. https:\/\/doi.org\/10.1128\/mcb.8.6.2651-2654.1988","journal-title":"Mol Cell Biol"},{"key":"1573_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.010","journal-title":"Semin Cancer Biol"},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1210\/jc.2012-2104","volume":"97","author":"C Li","year":"2012","unstructured":"Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559\u201370. https:\/\/doi.org\/10.1210\/jc.2012-2104","journal-title":"J Clin Endocrinol Metab"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1507\/endocrj.EJ20-0063","volume":"67","author":"JH Chung","year":"2020","unstructured":"Chung JH. BRAF and TERT promoter mutations: clinical application in thyroid cancer. Endocr J. 2020;67:577\u201384. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0063","journal-title":"Endocr J"},{"key":"1573_CR18","doi-asserted-by":"publisher","unstructured":"Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J. Risk and prognostic factors for BRAF(V600E) mutations in papillary thyroid carcinoma. Biomed Res Int. 2022;2022(9959649). https:\/\/doi.org\/10.1155\/2022\/9959649","DOI":"10.1155\/2022\/9959649"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373\u20139. https:\/\/doi.org\/10.1210\/jc.2005-0987","journal-title":"J Clin Endocrinol Metab"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.20945\/2359-3997000000285","volume":"64","author":"RS Scheffel","year":"2021","unstructured":"Scheffel RS, de Cristo AP, Romitti M, Vargas CVF, Ceolin L, Zanella AB, Dora JM, Maia AL. The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma. Arch Endocrinol Metab. 2021;64:751\u20137. https:\/\/doi.org\/10.20945\/2359-3997000000285","journal-title":"Arch Endocrinol Metab"},{"key":"1573_CR21","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718\u201326. https:\/\/doi.org\/10.1200\/JCO.2014.55.5094","journal-title":"J Clin Oncol"},{"key":"1573_CR22","first-page":"1519","volume":"4","author":"Y Ishizaka","year":"1989","unstructured":"Ishizaka Y, Itoh F, Tahira T, Ikeda I, Sugimura T, Tucker J, Fertitta A, Carrano AV, Nagao M. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene. 1989;4:1519\u201321.","journal-title":"Oncogene"},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1038\/s41388-021-02009-8","volume":"40","author":"AR Garcia-Rendueles","year":"2021","unstructured":"Garcia-Rendueles AR, Chenlo M, Oroz-Gonjar F, Solomou A, Mistry A, Barry S, Gaston-Massuet C, Garcia-Lavandeira M, Perez-Romero S, Suarez-Fari\u00f1a M, Pradilla-Dieste A, Dieguez C, Mehlen P, Korbonits M, Alvarez CV. RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. Oncogene. 2021;40:6354\u201368. https:\/\/doi.org\/10.1038\/s41388-021-02009-8","journal-title":"Oncogene"},{"key":"1573_CR24","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.3390\/ijms21197108","volume":"21","author":"AK Mahato","year":"2020","unstructured":"Mahato AK, Sidorova YA. RET receptor tyrosine kinase: role in neurodegeneration, obesity, and cancer. Int J Mol Sci. 2020;21:7108. https:\/\/doi.org\/10.3390\/ijms21197108","journal-title":"Int J Mol Sci"},{"key":"1573_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/cancers2020885","volume":"2","author":"RH Grogan","year":"2010","unstructured":"Grogan RH, Mitmaker EJ, Clark OH. The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers. 2010;2:885\u2013912. https:\/\/doi.org\/10.3390\/cancers2020885","journal-title":"Cancers"},{"key":"1573_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s100380050117","volume":"44","author":"Y Kitamura","year":"1999","unstructured":"Kitamura Y, Minobe K, Nakata T, Shimizu K, Tanaka S, Fujimori M, Yokoyama S, Ito K, Onda M, Emi M. Ret\/PTC3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet. 1999;44:96\u2013102. https:\/\/doi.org\/10.1007\/s100380050117","journal-title":"J Hum Genet"},{"key":"1573_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12253-018-0540-3","volume":"26","author":"MS Khan","year":"2020","unstructured":"Khan MS, Qadri Q, Makhdoomi MJ, Wani MA, Malik AA, Niyaz M, Masoodi SR, Andrabi KI, Ahmad R, Mudassar S. RET\/PTC gene rearrangements in thyroid carcinogenesis: assessment and clinico-pathological correlations. Pathol Oncol Res. 2020;26:507\u201313. https:\/\/doi.org\/10.1007\/s12253-018-0540-3","journal-title":"Pathol Oncol Res"},{"key":"1573_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12902-024-01586-5","volume":"24","author":"Y Huang","year":"2024","unstructured":"Huang Y, Lin P, Liao J, Liang F, Han P, Fu S, Jiang Y, Yang Z, Tan N, Huang J, Chen R, Ouyang N, Huang X. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma. BMC Endocr Disord. 2024;24:68. https:\/\/doi.org\/10.1186\/s12902-024-01586-5","journal-title":"BMC Endocr Disord"},{"key":"1573_CR29","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.1245\/s10434-024-15500-9","volume":"31","author":"DW Scholfield","year":"2024","unstructured":"Scholfield DW, Fitzgerald CWR, Boe LA, Eagan A, Levyn H, Xu B, Tuttle RM, Fagin JA, Shaha AR, Shah JP, Wong RJ, Patel SG, Ghossein R, Ganly I. Defining the genomic landscape of diffuse sclerosing papillary thyroid carcinoma: prognostic implications of RET fusions. Ann Surg Oncol. 2024;31:5525\u201336. https:\/\/doi.org\/10.1245\/s10434-024-15500-9","journal-title":"Ann Surg Oncol"},{"key":"1573_CR30","doi-asserted-by":"publisher","first-page":"589929","DOI":"10.3389\/fimmu.2020.589929","volume":"11","author":"M Dratwa","year":"2020","unstructured":"Dratwa M, Wysocza\u0144ska B, \u0141acina P, Kubik T, Bogunia-Kubik K. TERT-regulation and roles in cancer formation. Front Immunol. 2020;11:589929. https:\/\/doi.org\/10.3389\/fimmu.2020.589929","journal-title":"Front Immunol"},{"key":"1573_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/jclinpath-2018-205653","volume":"72","author":"AJ Colebatch","year":"2019","unstructured":"Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. J Clin Pathol. 2019;72:281\u20134. https:\/\/doi.org\/10.1136\/jclinpath-2018-205653","journal-title":"J Clin Pathol"},{"key":"1573_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1089\/thy.2015.0488","volume":"26","author":"SE Lee","year":"2016","unstructured":"Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK, Yang JH. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population. Thyroid. 2016;26:901\u201310. https:\/\/doi.org\/10.1089\/thy.2015.0488","journal-title":"Thyroid"},{"key":"1573_CR33","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","volume":"99","author":"X Liu","year":"2014","unstructured":"Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99:E1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2013-4048","journal-title":"J Clin Endocrinol Metab"},{"key":"1573_CR34","doi-asserted-by":"publisher","first-page":"540238","DOI":"10.3389\/fonc.2020.540238","volume":"10","author":"L Zhao","year":"2020","unstructured":"Zhao L, Wang L, Jia X, Hu X, Pang P, Zhao S, Wang Y, Wang J, Zhang Y, Lyu Z. The coexistence of genetic mutations in thyroid carcinoma predicts histopathological factors associated with a poor prognosis: a systematic review and network meta-analysis. Front Oncol. 2020;10:540238. https:\/\/doi.org\/10.3389\/fonc.2020.540238","journal-title":"Front Oncol"},{"key":"1573_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12020-024-03722-6","volume":"85","author":"Y Sang","year":"2024","unstructured":"Sang Y, Hu G, Xue J, Chen M, Hong S, Liu R. Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer. Endocrine. 2024;85:304\u201312. https:\/\/doi.org\/10.1007\/s12020-024-03722-6","journal-title":"Endocrine"},{"key":"1573_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13000-020-00962-8","volume":"15","author":"M Li","year":"2020","unstructured":"Li M, Jia H, Qian Q, Wen P, Chen C, Hua Y, Wang K, Zhang W, Shi F. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population. Diagn Pathol. 2020;15:49. https:\/\/doi.org\/10.1186\/s13000-020-00962-8","journal-title":"Diagn Pathol"},{"key":"1573_CR37","first-page":"4459","volume":"48","author":"NR Lemoine","year":"1988","unstructured":"Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988;48:4459\u201363.","journal-title":"Cancer Res"},{"key":"1573_CR38","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/ERC-15-0070","volume":"22","author":"MM Moura","year":"2015","unstructured":"Moura MM, Cavaco BM, Leite V. RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer. 2015;22:R235\u2013252. https:\/\/doi.org\/10.1530\/ERC-15-0070","journal-title":"Endocr Relat Cancer"},{"key":"1573_CR39","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Cancer Res. 2020;80:2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682","journal-title":"Cancer Res"},{"key":"1573_CR40","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"key":"1573_CR41","doi-asserted-by":"publisher","first-page":"100570","DOI":"10.1016\/j.esmoop.2022.100570","volume":"7","author":"S Schmid","year":"2022","unstructured":"Schmid S, Jochum W, Padberg B, Demmer I, Mertz KD, Joerger M, Britschgi C, Matter MS, Rothschild SI, Omlin A. How to read a next-generation sequencing report-what oncologists need to know. ESMO Open. 2022;7:100570. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100570","journal-title":"ESMO Open"},{"key":"1573_CR42","doi-asserted-by":"publisher","first-page":"e1359","DOI":"10.1002\/onco.13783","volume":"26","author":"M Shirdarreh","year":"2021","unstructured":"Shirdarreh M, Aziza O, Pezo RC, Jerzak KJ, Warner E. Patients\u2019 and oncologists\u2019 knowledge and expectations regarding tumor multigene next-generation sequencing: a narrative review. Oncologist. 2021;26:e1359\u201371. https:\/\/doi.org\/10.1002\/onco.13783","journal-title":"Oncologist"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01573-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-024-01573-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-024-01573-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:07:36Z","timestamp":1731661656000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-024-01573-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1186\/s13000-024-01573-3","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research ethics was approved by the ethics committee of Fujian Medical University Union Hospital(2024KJCX105).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}